| [1] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
|
| [2] |
Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases[J]. Oncologist, 2007, 12(7): 884-898.
|
| [3] |
Christensen TD, Spindler KL, Palshof JA, et al. Systematic review: brain metastases from colorectal cancer--Incidence and patient characteristics[J]. BMC Cancer, 2016, 16: 260.
|
| [4] |
Sundermeyer ML, Meropol NJ, Rogatko A, et al. Changing patterns of bone and brain metastases in patients with colorectal cancer[J]. Clin Colorectal Cancer, 2005, 5(2): 108-113.
|
| [5] |
Mege D, Sans A, Ouaissi M, et al. Brain metastases from colorectal cancer: characteristics and management[J]. ANZ J Surg, 2018, 88(3): 140-145.
|
| [6] |
Chahine G, Ibrahim T, Felefly T, et al. Colorectal cancer and brain metastases: An aggressive disease with a different response to treatment[J]. Tumori, 2019, 105(5): 427-433.
|
| [7] |
Achrol AS, Rennert RC, Anders C, et al. Brain metastases[J]. Nat Rev Dis Primers, 2019, 5(1): 5.
|
| [8] |
Taylor G, Karlin N, Halfdanarson TR, et al. Leptomeningeal carcinomatosis in colorectal cancer: The mayo clinic experience[J]. Clin Colorectal Cancer, 2018, 17(2): e183-e187.
|
| [9] |
Purandare NC, Puranik A, Shah S, et al. Common malignant brain tumors: can 18F-FDG PET/CT aid in differentiation[J]. Nucl Med Commun, 2017, 38(12): 1109-1116.
|
| [10] |
Noura S, Ohue M, Shingai T, et al. Brain metastasis from colorectal cancer: prognostic factors and survival[J]. J Surg Oncol, 2012, 106(2): 144-148.
|
| [11] |
Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)[J]. Neuro Oncol, 2017, 19(2): 162-174.
|
| [12] |
Rades D, Hansen HC, Janssen S, et al. Diagnosis-specific WBRT-30-CRC score for estimating survival of patients irradiated for brain metastases from colorectal cancer[J]. Anticancer Res, 2019, 39(5): 2569-2574.
|
| [13] |
Rades D, Panzner A, Dziggel L, et al. Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis[J]. Cancer, 2012, 118(15): 3852-3859.
|
| [14] |
Rades D, Dziggel L, Blanck O, et al. A score to identify patients with brain metastases from colorectal cancer who may benefit from whole-brainr adiotherapy in addition to stereotactic radiosurgery/radiotherapy[J]. Anticancer Res, 2018, 38(5): 3111-3114.
|
| [15] |
Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial[J]. J Clin Oncol, 2014, 32(34): 3810-3816.
|
| [16] |
Schoeggl A, Kitz K, Reddy M, et al. Stereotactic radiosurgery for brain metastases from colorectal cancer[J]. Int J Colorectal Dis, 2002, 17(3): 150-155.
|
| [17] |
Hasegawa T, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for brain metastases from gastrointestinal tract cancer[J]. Surg Neurol, 2003, 60(6): 506-514; discussion 514-515.
|
| [18] |
Kosaki K, Shibamoto Y, Hirai T, et al. Regression curves of brain metastases after gamma knife irradiation: Difference by tumor and patient characteristics[J]. Cancer Sci, 2012, 103(11): 1967-1973.
|
| [19] |
Skeie BS, Enger PØ, Ganz JC, et al. Gamma knife surgery of colorectal brain metastases: a high prescription dose of 25 Gy may improve growth control[J]. World Neurosurg, 2013, 79(3-4): 525-536.
|
| [20] |
Jung M, Ahn JB, Chang JH, et al. Brain metastases from colorectal carcinoma: prognostic factors and outcome[J]. J Neurooncol, 2011, 101(1): 49-55.
|
| [21] |
Kim HJ, Huh JW, Jung TY, et al. Clinical outcome with gamma-knife surgery or surgery for brain metastases from colorectal cancer[J]. J Clin Neurosci, 2013, 20(10): 1417-1421.
|
| [22] |
Finkelmeier F, You SJ, Waidmann O, et al. Bevacizumab in combination with chemotherapy for colorectal brain metastasis[J]. J Gastrointest Cancer, 2016, 47(1): 82-88.
|
| [23] |
Yoshida Y, Hoshino S, Aisu N, et al. Efficacy of XELOX plus bevacizumab in brain metastasis from rectal cancer[J]. Case Rep Oncol, 2014, 7(1): 117-121.
|
| [24] |
Tokoro T, Nakamura K, Hirose A, et al. A case of colon cancer with brain, liver and lung metastasis successfully treated with bevacizumab plus xelox therapy[J]. Gan To Kagaku Ryoho, 2018, 45(3): 521-523.
|
| [25] |
Ogawa S, Fujishiro H, Fujiwara A, et al. A case of long-term survival in stage IV squamous cell carcinoma of the anal canal with multidisciplinary treatment[J]. Nihon Shokakibyo Gakkai Zasshi, 2017, 114(11): 1987-1995.
|
| [26] |
Nebot-Bral L, Coutzac C, Kannouche PL, et al. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors[J]. Bull Cancer, 2018 .
|
| [27] |
Ott PA, Hodi FS, Kaufman HL, et al. Combination immunotherapy: a road map[J]. J Immunother Cancer, 2017, 5: 16.
|
| [28] |
Wei SC, Levine JH, Cogdill AP, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade[J]. Cell, 2017, 170(6): 1120-1133.e17.
|
| [29] |
Overman MJ, Lonardi S, KYM W, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8): 773-779.
|
| [30] |
Lehrer EJ, Peterson J, Brown PD, et al. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data[J]. Radiother Oncol, 2019, 130: 104-112.
|